Zynex Medical Holdings, Inc. (OTCBB: ZYNX), a provider of pain management systems and electrotherapy products for medical patients with functional disability, announces it has leased additional office space in close proximity to its existing location. Zynex has signed a 25-month lease for a 16,553-square-foot mixed office and warehouse at 8022 Southpark Circle, Littleton, CO 80120.
Thomas Sandgaard, CEO, explains: “Our recent growth has made it necessary for us to lease office and warehouse space to accommodate not only a higher level of activity as well as anticipated future growth. We continue to outsource many functions, such as electronic assembly, in an effort to have as much flexibility in our growth as possible. We expect to move into the new space immediately. We will be filing a Current Report on Form 8-K with the Securities and Exchange Commission that will contain additional information concerning the lease.”
About Zynex Medical Holdings, Inc.
Zynex Medical Holdings, Inc. (founded in 1996) engineers, manufactures, markets and sells its own design of electrotherapy medical devices in two distinct markets: standard digital electrotherapy products for pain relief and pain management; and the NeuroMove(TM) for stroke and spinal cord injury (SCI) rehabilitation. Zynex's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain.
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, our dependence on third party manufacturers to produce our goods on time and to our specifications, the acceptance of our products by hospitals and clinicians, implementation of our sales strategy including a strong direct sales force and other risks described in our 10-KSB Report for the year ended December 31, 2006.
Zynex Medical Holdings, Inc.
Thomas Sandgaard, CEO, 303-703-4906
www.zynexmed.com